Jordi Bruix

Grupo de investigación

Oncología hepática (BCLC) Emeritus researcher

jbruix@clinic.cat 0000-0002-9826-0753

Publicaciones destacadas

Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial

Autores:
Finn RS; Merle P; Granito A; Huang YH; Bodoky G;

(...)

Sun W; LeBerre MA; Baumhauer A; Meinhardt G; Bruix J.

Referencia: Journal Of Hepatology 2018.
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Autores:
Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V;

(...)

Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J .

Referencia: Lancet Oncology 2018.
Hepatocellular carcinoma

Autores:
Forner A; Reig M; Bruix J;

Referencia: Lancet 2018.
Complete response under sorafenib in patients with hepatocellular carcinoma. Relationship with dermatologic adverse events.

Autores:
Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F;

(...)

Huertas C; Minguez B; Ayuso C; Bruix J; Reig M .

Referencia: Hepatology 2018.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Autores:
Bruix, Jordi; Qin, Shukui; Merle, Philippe; Granito, Alessandro; Huang, Yi-Hsiang;

(...)

Finn, Richard S.; LeBerre, Marie-Aude; Baumhauer, Annette; Meinhardt, Gerold; Han, Guohong;Resorce Investigators.

Referencia: Lancet 2017.
Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution

Autores:
Reig M; Mariño Z; Perelló C; Iñarrairaegui M; Ribeiro A;

(...)

Varela M; Sangro B; Calleja JL; Forns X; Bruix J .

Referencia: Journal Of Hepatology 2016.
Liver transplantation for 'very early' intrahepatic cholangiocarcinoma. international retrospective study supporting a prospective assessment

Autores:
Sapisochin G; Facciuto M; Rubbia-Brandt L; Marti J; Mehta N;

(...)

Majno P; Kneteman N; Saunders C; Bruix J; iCCA International Consortium.

Referencia: Hepatology 2016.
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma

Autores:
Bruix J; Reig M; Sherman M ;

Referencia: Gastroenterology 2016.
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

Autores:
Bruix, Jordi; Takayama, Tadatoshi; Mazzaferro, Vincenzo; Chau, Gar-Yang; Yang, Jiamei;

(...)

Makuuchi, Masatoshi; Souza, Fabricio; Le Berre, Marie-Aude; Meinhardt, Gerold; Llovet, Josep M.;STORM Investigators.

Referencia: Lancet Oncology 2015.
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib

Autores:
Reig, Maria; Torres, Ferran; Rodriguez-Lope, Carlos; Forner, Alejandro; Llarch, Neus;

Rimola, Jordi; Darnell, Anna; Rios, Jose; Ayuso, Carmen; Bruix, Jordi.

Referencia: Journal Of Hepatology 2014.

Proyectos destacados

A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

Investigador/a principal: Jordi Bruix Tudo

Financiador: Adaptimmune

Código: ADP-0033-001

Duración: 01/01/2018 - 31/12/2033
Role and therapeutic potential of CPEB proteins in the transition from cirrhosis to hepatocellular carcinoma.

Investigador/a principal: Jordi Bruix Tudo

Financiador: Worldwide Cancer Research (former AICR)

Código: 16-0026_BRUIX

Duración: 01/02/2016 - 31/12/2019
A prospective, multicentre, randomised, controlled study evaluating SIR-Spheres® Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM)

Investigador/a principal: Jordi Bruix Tudo

Financiador: Sirtex

Código: SIRCCA

Duración: 03/01/2016
Molecular regulation of the progression from hepatic steatosis to cirrhosis and hepatocellular carcinoma: Role and therapeutic potential of CPEB proteins.

Investigador/a principal: Jordi Bruix Tudo

Financiador: Asociación Española Contra el Cáncer

Código: GCB15152955MEND

Duración: 01/02/2015 - 31/12/2020
A Phase 1/2, Dose-escalation, Open-label Study of Nivolumab or Nivolumab in Combination with Other Agents in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis

Investigador/a principal: Jordi Bruix Tudo

Financiador: BRISTOL-MYERS SQUIBB

Código: CA209040

Duración: 01/02/2015

Jordi Bruix

Grupo de investigación

Publicaciones destacadas

Proyectos destacados

A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

Role and therapeutic potential of CPEB proteins in the transition from cirrhosis to hepatocellular carcinoma.

A prospective, multicentre, randomised, controlled study evaluating SIR-Spheres® Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM)

Molecular regulation of the progression from hepatic steatosis to cirrhosis and hepatocellular carcinoma: Role and therapeutic potential of CPEB proteins.

A Phase 1/2, Dose-escalation, Open-label Study of Nivolumab or Nivolumab in Combination with Other Agents in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis

Suscríbete a la Newsletter del Clínic